Výsledky vyhledávání - "Diane Dan Wang"

Modeling of pharmacodynamic (PD) biomarkers (BM) related to CDK4/6 inhibition and exploratory BM-response (progression free survival [PFS]) analyses in patients with advanced breast cancer

Autor: Diane Dan Wang, Yuan Liu, Yanke Yu

Publikováno v: Journal of Clinical Oncology. 37:e14528-e14528

e14528 Background: Palbociclib (PAL) is an oral inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6) approved for advanced breast cancer (ABC). In a clinical trial, the expression levels of PD BMs related to PAL effect, including thymidine kinase (T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::81c72b1fac92d0d89d5d07f6607eb42a
https://doi.org/10.1200/jco.2019.37.15_suppl.e14528

Zobrazit plný text záznamu

Palbociclib exposure-response analyses in second-line treatment of hormone-receptor positive advanced breast cancer (ABC)

Autor: Massimo Cristofanilli, Wan Sun, Yanke Yu, Diane Dan Wang, Nicholas C. Turner, Justin Hoffman

Publikováno v: Journal of Clinical Oncology. 35:1053-1053

1053 Background: Palbociclib (PAL) is an oral inhibitor of cyclin-dependent kinases 4 and 6 approved for ABC. Exposure-response analyses for efficacy and safety endpoints were performed to evaluate the current PAL clinical dosing regimen (125 mg dail

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7e9fdb9e82da693e5ee13520300a10fb
https://doi.org/10.1200/jco.2017.35.15_suppl.1053

Zobrazit plný text záznamu

An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 2 study of palbociclib (an oral CDK4/6 inhibitor) plus cetuximab in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)

Autor: Holger Thurm, Jin-Ching Lin, Jean-Francois Martini, Diane Dan Wang, Assuntina G. Sacco, Douglas Adkins, Shaw Ling Wang, Bohuslav Melichar, Bhumsuk Keam, Tara Baney, Justin Hoffman, Makoto Tahara

Publikováno v: Journal of Clinical Oncology. 34:TPS6102-TPS6102

TPS6102Background: SCCHN is the sixth most common cancer worldwide. Current second-line treatments for human papillomavirus (HPV)–negative, R/M SCCHN have marginal effectiveness and significant tox...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f0ab58f1375c9d06168ec555b8e653d6
https://doi.org/10.1200/jco.2016.34.15_suppl.tps6102

Zobrazit plný text záznamu

Population pharmacokinetics (PK) of tremelimumab in patients (pts) with melanoma

Autor: Diane Dan Wang, P. Hsyu, D. Kang, M. Amantea, Erjian Wang

Publikováno v: Journal of Clinical Oncology. 27:3048-3048

3048 Background: Tremelimumab is a fully human monoclonal antibody targeted against CTLA4, a protein on T cells critical for regulating T-cell activities, which is under development for treatment of various cancers, including melanoma. Population PK

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5463ae5ef50b521929ed5f0006fa8757
https://doi.org/10.1200/jco.2009.27.15_suppl.3048

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání